<DOC>
	<DOC>NCT03088358</DOC>
	<brief_summary>To evaluate influence of therapy on the following efficacy and safety parameters in different TeaRx dose groups and Enoxaparin group: - Total venous thromboembolic events (VTE), which includes confirmed deep venous thrombosis (DVT), nonfatal pulmonary embolism (PE), and total mortality - Incidence of DVT (total, proximal, distal) - Incidence of nonfatal PE - Incidence of symptomatic VTE (DVT, PE) - VTE caused mortality - Non-VTE caused mortality - Incidence of all hemorrhagic complications - Incidence of major and clinically relevant non-major bleeding - Adverse events (AEs) and serious adverse events (SAEs) from subject complaints, physical examination, vital signs, laboratory results</brief_summary>
	<brief_title>Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<criteria>Male or female, age ≥ 18 years; Planned total knee replacement surgery; Signed informed consent form; Willing to comply with the protocol; Willing to use adequate contraception during the trial. Surgery for acute fracture 4 weeks before screening; history of septic inflammation in the joint; prosthesis revision or one leg missing History of venous thrombosis of any location or PE History of heparin induced thrombocytopenia or other thrombocytopathy; hemorrhagic diathesis History of evident coagulopathy or in a relative Congenital thrombophilia Bleeding within 6 months of screening; increased risk of bleeding BMI less than 18,5 or more than 40 kg/m2 Systolic BP &gt; 180 mmHg and/or diastolic BP &gt; 110 mmHg registered twice within 1530 minutes Hb ≤ 10.5 g/dL in female or ≤ 11.5 g/dL in male Platelets &lt; 100 000/mm3 Clinical significant abnormalities of APTT and/or INR GFR &lt; 30 ml/min/1.73 m2 ALT or AST ≥ 2 x ULN or total bilirubin ≥1,5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>